KHAN Technology Transfer Fund II

KHAN Technology Transfer Fund II (KHAN-II) is a specialized venture capital fund dedicated to bridging the gap between academic research and industrial drug development. Managed by KHAN Management GmbH, the fund focuses on identifying and financing innovative drug discovery projects, primarily originating from the Max Planck Society and other leading European academic institutions. KHAN-II operates in close partnership with the Lead Discovery Center (LDC), leveraging professional drug discovery infrastructure to advance academic assets toward clinical readiness. The fund targets a broad range of therapeutic areas, including oncology, inflammation, and rare diseases, with the primary goal of developing high-quality lead candidates for out-licensing or the formation of spin-off companies. By providing both capital and professional project management, KHAN-II addresses the critical funding gap in early-stage translational medicine.